Sanofi (SNY) EBITDA (2009 - 2026)

Sanofi has disclosed EBITDA across 18 years of filings, most recently posting $2.5 billion for Q1 2026.

• EBITDA for Q1 2026 came in at $2.5 billion, up 3.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.2 billion (down 15.84% YoY), and the FY2025 annual result was $7.4 billion, down 4.71% from the prior year.
• EBITDA came in at $2.5 billion for Q1 2026 at Sanofi, up from -$5.6 billion in the prior quarter.
• In the past five years, EBITDA ranged from a high of $8.6 billion in Q3 2025 to a low of -$5.6 billion in Q4 2025.
• The 5-year median for EBITDA is $2.5 billion (2026), against an average of $2.6 billion.
• Across the five-year window, EBITDA surged 148.25% in 2022 and slumped 1011.95% in 2025, its largest moves.
• Sanofi's EBITDA stood at $4.2 billion in 2022, then jumped by 78.89% to $7.5 billion in 2023, then slumped by 91.82% to $612.3 million in 2024, then plunged by 1011.95% to -$5.6 billion in 2025, then surged by 144.47% to $2.5 billion in 2026.
• The last three EBITDA figures came in at $2.5 billion (Q1 2026), -$5.6 billion (Q4 2025), and $8.6 billion (Q3 2025), per Business Quant data.